Kintor Pharma Announces Dosing of First Subject in US Phase I Clinical Trial of GT20029 for Androgenic Alopecia and Acne_Kintor Pharmaceutical Limited
Kintor Pharma Announces Dosing of First Subject in US Phase I Clinical Trial of GT20029 for Androgenic Alopecia and Acne-Kintor Pharmaceutical Limited-Suzhou, February 3, 2022 - Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing...
en.kintor.com.cn